Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Contineum Therapeutics, Inc. (CTNM) had Return on Tangible Equity of -5.78% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-14.46M |
|
-- |
|
-- |
|
$16.90M |
|
$-16.90M |
|
$2.45M |
|
$-14.46M |
|
$-14.46M |
|
$-14.46M |
|
$-14.46M |
|
$-14.46M |
|
$-14.46M |
|
$-16.90M |
|
$-16.82M |
|
37.34M |
|
37.34M |
|
$-0.39 |
|
$-0.39 |
|
| Balance Sheet Financials | |
$252.96M |
|
$1.06M |
|
$8.38M |
|
$261.35M |
|
$6.66M |
|
-- |
|
$4.65M |
|
$11.31M |
|
$250.04M |
|
$250.04M |
|
$250.04M |
|
37.39M |
|
| Cash Flow Statement Financials | |
$-16.27M |
|
$-39.31M |
|
$0.13M |
|
$75.60M |
|
$20.16M |
|
$-55.45M |
|
$3.82M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
38.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-16.58M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-5.78% |
|
|
Return on Tangible Equity |
-5.78% |
-5.53% |
|
-5.78% |
|
$6.69 |
|
$-0.44 |
|
$-0.44 |
|